Colorectal Cancer

The FDA has approved Guardant Health’s Shield blood test to screen for colorectal cancer in patients aged 45 years and older at average risk for disease, according to a company press release.

Reductions in unprocessed red meat and processed meat consumption by 30% over a decade led to substantial reductions in chronic diseases and mortality among adults in the United States, a microsimulation study showed.

Timing of adjuvant chemotherapy initiation may affect outcomes among patients who undergo surgery for colorectal cancer, according to data published in JAMA Surgery.

Cancer survivors with the lowest socioeconomic status appeared twice as likely to die of CVD than those with the highest household incomes, according to a study published in European Heart Journal – Quality of Care and Clinical Outcomes.

AI has already made its mark in gastroenterology as a tool for detecting gastrointestinal lesions, adenomas and inflammatory bowel disease. However, its next phase of evolution might seem the most unlikely: Aiding colonoscopy preparation.

Although adherence to standardized reporting guidelines ranged from 82.4% to 92.2% in published trials of colorectal cancer screening, researchers found that reporting of trial registration and informed consent materials could be improved.

Using fecal hemoglobin concentrations to guide colorectal cancer screening intervals reduced the number of fecal immunochemical tests and colonoscopies by 49% and 28%, respectively, compared with biennial screening, data showed.

The FDA granted accelerated approval adagrasib with cetuximab for the treatment of KRASG12C -mutated locally advanced or metastatic colorectal cancer, according to a press release from the agency.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.

CHICAGO — A phase 2 study evaluating dostarlimab in adults with mismatch repair-deficient locally advanced rectal cancer has maintained a 100% clinical complete response rate at a median follow-up of almost 18 months.